CNDR Welcomes Dr. Hugh McMillan as New Pediatric Lead
Dr. Hugh McMillan
The Canadian Neuromuscular Disease Registry (CNDR) announced in February 2024 that Pediatric Lead Dr. Craig Campbell has decided to step down from his role, passing the torch to Dr. Hugh McMillan.
As the registry embarks on this transition, the CNDR warmly welcome Dr. McMillan as the new Pediatric Lead and are grateful for the wealth of knowledge, expertise, and leadership he will bring to the role.
Dr. Craig Campbell
National Principal Investigator Dr. Lawrence Korngut, CNDR investigators, and the CNDR National Office Team extend their heartfelt gratitude to Dr. Craig Campbell for his exceptional contributions and passionate support as co-founder and Pediatric Lead for the CNDR. Since the inception of the CNDR, Dr. Campbell has played a pivotal role, co-founding the registry in 2010. He has been integral to multiple disease working groups, including SMA, DMD, LGMD, DM, and CMS, offering invaluable guidance and expertise. As the CNDR’s Pediatric Lead Investigator, he has been instrumental in navigating the complex landscape of neuromuscular research, ensuring CNDR’s activities align with the evolving needs of their community. Dr Campbell, alongside Victoria Hodgkinson, also worked to integrate the CNDR within the global neuromuscular registry network of TREAT-NMD, and for 6 years led the global registry committee TGDOC, based largely on the strength and substantial contributions of the CNDR to the international efforts to make an impact for children and families living with neuromuscular diseases. Dr. Campbell’s passion and leadership have been catalysts in fostering collaboration and driving impactful outcomes for patients, and the CNDR are gratitude for his dedication and commitment.
Read next...
NMD4C Launch Survey to Assess Familiarity and Experience in Outcome Measures in NMDs
As we anticipate novel treatments for other neuromuscular conditions, we would like to understand your familiarity and experience with the outcome measures in clinical trials underway or for treatments for NMDs approved in other jurisdictions through a short survey.
Dr. Cynthia Gagnon Receives 2024 Steinert Award, IDMC-15 Meeting to Take Place in Saguenay
We are pleased to share that NMD4C steering committee member Dr. Cynthia Gagnon was honoured with a Steinert Award at the recent International Myotonic Dystrophy Consortium Meeting (IDMC-14) in Nijmegen, Netherlands!
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.